SYN.AI
LIVE

Serial Number

98092280

Owner

SYNGENE INTERNATIONAL LIMITED

Attorney

Michelle P. Ciotola

Filing Date

Jul 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SYN.AI Trademark

Serial Number: 98092280

SYN.AI is a trademark filed by SYNGENE INTERNATIONAL LIMITED on July 19, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 39 (Transportation & Storage), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

SYNGENE INTERNATIONAL LIMITED (13 trademarks)

Biocon Special Economic Zone,Biocon Park
Link Rd, Bangalore Karnataka , IN

Entity Type: 03

Trademark Details

Filing Date

July 19, 2023

Registration Date

Not Registered

Published for Opposition

December 3, 2024

Goods & Services

Treatment of materials by polymerization; custom manufacture of pharmaceuticals, chemotherapy drugs, antibiotic medicines, medicines, drugs by pharmaceutical compounders; contract manufacturing in the field of pharmaceuticals and drug development

Bio-technological products, namely, enzymes for scientific and research purposes, protein for industrial use, carbohydrates used as an ingredient in the manufacture of nutraceuticals, lipids used in the manufacture of cosmetics, beverages, food products and food supplements, and nucleic acids for scientific purposes, DNA products, namely, DNA polymerase, DNA polymerase formulations, immunological re-agents for scientific purposes, and fine industrial chemicals featuring organic intermediates; active chemical ingredients for use in the manufacture of pharmaceuticals for treating inflammation, metabolic disorders, oncology/immune-oncology, central nervous system disorders, pain and cardiovascular and renal disorders, anti-infective and fibrosis treatments, ophthalmic disorders; chemicals for use in the agrochemical industry; assays for research purposes; biomedical compounds, namely, peptide substrates used in analysing and detecting certain toxins for laboratory, research, clinical or medical laboratory use; unprocessed chemical polymers; chemicals for use in biotechnological product development; chemicals, namely, chitosan; chemicals, namely, chitosan for industrial purposes; aldehydes; chromatography chemicals; cells for scientific, laboratory or medical research; reagents for scientific use in the development of hybridoma antibodies, other than for medical or veterinary purposes; nucleic acid sequences and chemical reagents for other than medical and veterinary purposes; nucleotides for scientific and research use; protein arrays and nucleotide arrays for scientific and medical research; peptides substrates for industrial purposes; proteins for industrial use in recombinant DNA technology, other than for medical use; specialty chemicals, namely, chemical additives for general industrial use in the manufacture of a wide variety of goods; chemicals for use in science and industry; isotopes for industrial purposes; biochemicals for in vitro and in vivo scientific use; biochemicals for in vitro and in vivo scientific use; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; assays for research purposes; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; chemical preparations for use in DNA analysis in laboratories, other than for medical or veterinary purposes; proteins for use in recombinant DNA technology

Biomedical services, namely, the storage of human cells for medical use

Biological and bio-technological pharmaceutical preparations for the treatment of inflammation, metabolic disorders, oncology/immune-oncology, central nervous system disorders, pain and cardiovascular and renal disorders, anti-infective and fibrosis treatments, ophthalmic disorders; drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; antibodies for medical purposes; synthetic peptides for pharmaceutical purposes for the treatment of inflammation, metabolic disorders, oncology/immune-oncology, central nervous system disorders, pain and cardiovascular and renal disorders, anti-infective and fibrosis treatments, ophthalmic disorders; aldehydes for pharmaceutical purposes; imaging agents for magnetic resonance imaging (MRI); nucleic acid sequences and chemical reagents for medical and veterinary purposes; pharmaceutical preparations and substances for use in oncology; biological tissue grafts; vascular grafts; biopharmaceuticals for the treatment of cancer; yeast and yeast extracts for medical, veterinary or pharmaceutical purposes; protein arrays for medical diagnostic purposes; medicines for veterinary purposes for the treatment of inflammation, metabolic disorders, oncology/immune-oncology, central nervous system disorders, pain and cardiovascular and renal disorders, anti-infective and fibrosis treatments, ophthalmic disorders; isotopes for medical purposes; biological preparations for use in cell cultures for medical purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids

Scientific research and custom synthesis in the nature of chemical engineering; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing of materials; laboratory testing services for research purposes; testing of pharmaceuticals; chemical engineering; chemical analysis; drug discovery services; pharmaceutical drug development services; pharmaceutical product development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of companion animals, commercial livestock and wild animals; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; scientific research in the nature of conducting clinical trials for others in the field of chemical engineering; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific research services relating to the isolation and cultivation of human tissues and cells; preparation of reports relating to scientific and technical research; biochemical analysis in the field of molecular biology; contract scientific research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific laboratory services; services of a chemical or biological scientific laboratory; laboratory research services relating to pharmaceuticals; scientific research and development and scientific research consultation in the fields of antibodies, antibody technology, chemistry, agrochemical pharmaceuticals, bioinformatics, biomedical, biologics, biotechnology, bio therapeutics, biology, biochemical, cell line, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymer, peptide synthesis, protein, solid state characterization; toxicokinetic, scientific and technological services, namely, scientific research, development, design, testing, and engineering in the fields of antibody, API, biomolecules, cell bank characterization, chiral, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, gene, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nano particle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines

Business services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, large molecule development, antibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development

Medical diagnostic testing, monitoring and reporting services; preparation of reports relating to medical matters; medical testing of urine; medical pathology services

Filing History

STATEMENT OF USE PROCESSING COMPLETE
May 20, 2026 SUPC
USE AMENDMENT FILED
Jan 14, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Jan 14, 2026 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 15, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jul 14, 2025 EX1G
SOU EXTENSION 1 FILED
Jul 14, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 14, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 14, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 6, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 5, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 5, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 27, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 27, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 27, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 27, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 27, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 27, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 25, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 17, 2023 NWOS
NEW APPLICATION ENTERED
Jul 22, 2023 NWAP